期刊文献+

阿仑膦酸钠治疗2型糖尿病骨质疏松病人的效果及对骨代谢指标的影响 预览

Effect of Alendronate in treating patients with type 2 diabetes(T2DM)osteoporosis and its influence on bone metabolic markers
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨阿仑膦酸钠治疗2型糖尿病(T2DM)骨质疏松病人的临床效果。方法选取承德钢铁集团有限公司职工医院2016年3月至2017年3月收治的120例T2DM骨质疏松病人,其中研究组60例采用阿仑膦酸钠治疗,对照组60例采用钙尔奇D治疗,对比两组的治疗效果。结果治疗前,两组病人的L2、L3、L4腰椎、股骨颈的骨密度值差异无统计学意义(P>0.05);治疗后两组病人的L2、L3、L4腰椎、股骨颈的骨密度值较治疗前均显著提高(P<0.05),研究组病人的L2、L3、L4腰椎、股骨颈的骨密度值显著高于对照组(P<0.05);治疗前,两组病人的血清骨钙素(BGP)、碱性膦酸酶(BAP)、人抗酒石酸酸性膦酸酶5b(TRAP-5b)、血清钙、血Ⅰ型胶原N末端肽(NTX)差异无统计学意义(P>0.05);治疗后,两组病人的血清BGP、血清钙值较治疗前均显著提高(P<0.05),两组病人的BAP、TRAP-5b、NTX较治疗前显著降低(P<0.05);治疗后,研究组病人的血清BGP、血清钙分别为(7.82±1.69)ng/mL,(2.40±0.20)mmol/L,显著高于对照组(P<0.05),研究组的BAP、TRAP-5b、NTX分别为(26.62±3.77)ng/mL、(2.71±0.43)ng/mL、(23.04±1.67)ng/mL,显著低于对照组(P<0.05)。结论阿仑膦酸钠治疗T2DM骨质疏松病人能有效调节其骨代谢水平、提升病人的骨密度。 Objective To investigate the clinical effect of Alendronate on type 2 diabetes mellitus(T2DM)patients with osteoporosis.Methods A hundred and twenty cases of T2DM osteoporosis admitted to Chengde Iron and Steel Group Co.,Ltd.Staff Hospital from March 2016 to March 2017 were selected,of which 60 cases in the study group were treated with Alendronate sodium,and 60 cases in the control group were treated with Calcium D.The treatment effect was compared between the two groups.Results Before treatment,there was no significant difference in bone density value(BMD)of L2,L3,L4 lumbar spine and femoral neck between the two groups(P>0.05).Values of BMD of L2,L3,L4 lumbar and femoral neck after treatment were significantly increased compared with those before treatment(P<0.05).The BMD values of L2,L3,L4 lumbar spine and femoral neck in study group were significantly higher than those in control group(P<0.05).Before treatment,there were no significant differences in BGP,BAP,TRAP-5b,serum calcium and NTX between the two groups(P>0.05).After treatment,serum BGP and serum calcium increased significantly compared with those before treatment(P<0.05),while the levels of BAP,TRAP-5b and NTX decreased significantly compared with those before treatment(P<0.05).The levels of serum BGP[(7.82±1.69)ng/mL]and serum calcium[(2.40±0.20)mmol/L]in the study group were significantly higher than those in the control group(P<0.05).The levels of BAP[(26.62±3.77)ng/mL],TRAP-5b[(2.71±0.43)ng/mL]and NTX[(23.04±1.67)ng/mL]in the study group were significantly lower than those in the control group(P<0.05).Conclusion Alendronate in the treatment of T2DM osteoporosis patients can effectively regulate the level of bone metabolism,and improve the patient s bone mineral density.
作者 刘福志 张殿尧 吴香萍 LIU Fuzhi;ZHANG Dianyao;WU Xiangping(Department of Orthopedics,Staff Hospital of Chengde Iron and Steel Group Co.,Ltd.,Chengde,Hebei 067102,China;Department of Surgery,Chengde Maternal and Child Healthcare Hospital,Chengde,Hebei 067000,China)
出处 《安徽医药》 CAS 2019年第6期1230-1233,共4页 Anhui Medical and Pharmaceutical Journal
关键词 阿仑膦酸钠 2型糖尿病 骨质疏松 骨代谢 Alendronate sodium Type 2 diabetes Osteoporosis Bone metabolism
  • 相关文献

参考文献14

二级参考文献172

共引文献229

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏